rezvilutamide + abiraterone

Rezvilutamide + abiraterone is an investigational combination therapy for prostate cancer, specifically being studied in metastatic hormone-sensitive prostate cancer (mHSPC). Rezvilutamide is a novel, orally bioavailable androgen receptor antagonist developed by Jiangsu Hengrui Medicine. It inhibits androgen receptor signaling with lower blood–brain barrier penetration than other agents in its class, potentially reducing central nervous system side effects. Abiraterone is a CYP17 inhibitor that blocks androgen biosynthesis and is commonly used with prednisone to manage side effects. The combination aims to provide dual blockade of the androgen axis—by inhibiting both the production of androgens (abiraterone) and their action at the receptor level (rezvilutamide)—to improve disease control in advanced prostate cancer[1][2][4][5].